Aladar A. Szalay
Affiliations: | 1962-1988 | Biological Sciences | Cornell University, Ithaca, NY, United States |
| 1973-1977 | Biology | California Institute of Technology, Pasadena, CA | |
| 1988-1995 | University of Alberta, Edmonton, Alberta, Canada | ||
| 1993-2003 | Biochemistry | Loma Linda University, Loma Linda, United States | |
| 2003- | Biochemistry | Julius-Maximilans-Universität Würzburg, Würzburg, Bayern, Germany | |
| 2009- | Radiation Oncology | University of California, San Diego, La Jolla, CA |
Area:
Molecular Biology, Neuroscience Biology, PharmacologyWebsite:
https://www.biozentrum.uni-wuerzburg.de/biochem/research-groups/szalay-group-molecular-oncology/members/szalay-aladar-prof-dr/Google:
"Aladár A. Szalay"Bio:
http://excelerate-conference.com/speaker/dr-aladar-a-szalay-phd/
https://www.worldcat.org/oclc/74439244
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC343774/
Mean distance: 53433
Children
Sign in to add trainee| Brian G. Ayre | grad student | 1989-1995 | University of Alberta (Chemistry Tree) |
| Zhong Deng | grad student | 2000 | Loma Linda University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Haddad D, Socci N, Chen CH, et al. (2016) Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy. Molecular Therapy Oncolytics. 3: 16008 |
| Pugalenthi A, Mojica K, Ady JW, et al. (2015) Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma. Cancer Gene Therapy |
| Tsoneva D, Stritzker J, Bedenk K, et al. (2015) Drug-Encoded Biomarkers for Monitoring Biological Therapies. Plos One. 10: e0137573 |
| Adelfinger M, Bessler S, Frentzen A, et al. (2015) Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy. Viruses. 7: 4075-92 |
| Kirscher L, Deán-Ben XL, Scadeng M, et al. (2015) Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer Agent. Theranostics. 5: 1045-57 |
| Kober C, Rohn S, Weibel S, et al. (2015) Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps. Journal of Translational Medicine. 13: 216 |
| Ady JW, Johnsen C, Mojica K, et al. (2015) Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma. Surgery |
| Eveno C, Mojica K, Ady JW, et al. (2015) Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis. Surgery. 157: 331-7 |
| Pencavel TD, Wilkinson MJ, Mansfield DC, et al. (2015) Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma. International Journal of Cancer. Journal International Du Cancer. 136: 965-76 |
| Cecil A, Gentschev I, Adelfinger M, et al. (2014) Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models. Bioengineered. 5: 319-25 |